secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aditxt, Inc. (ADTX)
CIK:        0001726711
Form:       8-K
Filed at:   2025-07-21T23:59:59+00:00
Accession:  0001213900-25-066145
Event type: other
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aditxt subsidiary Pearsanta targets prostate cancer test launch by end-2025; IPO spin-off planned
--------------------------------------------------------------------------------

- Pearsanta plans to launch a lab-developed test for prostate cancer using mitochondrial DNA detection by end of 2025.
- CEO Amro Albanna stated 70% of cancer deaths could be prevented if caught early; Pearsanta aims for early detection via non-invasive blood test.
- Aditxt plans to spin off Pearsanta via IPO, retaining ~60% ownership; values Aditxt's stake potentially at $60M vs. current $5M market cap.
- The test will initially run at CLIA/CAP lab in Richmond, VA; FDA submission for kit development planned later.
- Other subsidiaries highlighted: Adimune (autoimmunity) and pending Adifem/Evofem acquisition (women's health) expected to close by September 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1726711/000121390025066145/0001213900-25-066145-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1726711/000121390025066145/ea0249677-8k_aditxt.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-066145

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer